US 11129823
Combination treatment of ocular inflammatory disorders and diseases
granted A61KA61K31/165A61K31/192
Quick answer
US patent 11129823 (Combination treatment of ocular inflammatory disorders and diseases) held by Aldeyra Therapeutics, Inc. expires Mon Sep 23 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Aldeyra Therapeutics, Inc.
- Grant date
- Tue Sep 28 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Sep 23 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 4
- CPC classes
- A61K, A61K31/165, A61K31/192, A61K31/196, A61K31/436